Internal Medicine, Hematology & Oncology · Troy, OH
NPI
1598825085
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
855 W Market St
Troy, OH, 45373
Phone (937) 293-1622
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.1M
359,078 services
Medicare patients, 2024
621
Average age 76
Drug cost, 2024
$9.1M
2,215 prescriptions
Company payments, 2025
$2,345
From 40 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rajeev Kulkarni was code J1439 (injection, ferric carboxymaltose, 1 mg), 59,250 times for 25 patients. In total Rajeev Kulkarni billed 359,078 services in 111 codes, and Medicare paid $4.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-04-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 59,250 | 25 | $0.88 | $52K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 22,745 | 13 | $2.33 | $53K |
| J1756 Injection, iron sucrose, 1 mg | Office | 19,800 | 19 | $0.17 | $3,426 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 19,401 | 13 | $38.25 | $742K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 15,900 | 19 | $0.11 | $1,692 |
| J0897 Injection, denosumab, 1 mg | Office | 7,380 | 16 | $20.56 | $152K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,924 | 552 | $12.10 | $23K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,802 | 25 | $0.09 | $156 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,400 | 23 | $0.67 | $934 |
| 99214 Office E&M - Established | Office | 1,020 | 445 | $85.32 | $87K |
| 99215 Office E&M - Established | Office | 980 | 261 | $128.08 | $126K |
| 96413 Chemotherapy Administration | Office | 487 | 47 | $91.86 | $45K |
| 96401 Chemotherapy Administration | Office | 420 | 15 | $51.18 | $21K |
| 96372 Injection Administration | Office | 413 | 51 | $10.21 | $4,216 |
| 96375 Injection Administration | Office | 281 | 37 | $11.01 | $3,094 |
By year: 2022 $3.4M for 205,545 services; 2023 $4.2M for 289,645 services; 2024 $4.1M for 359,078 services.
Medicare prescription drug claims, 2024
In 2024, the drug Rajeev Kulkarni prescribed most often to Medicare patients was Anastrozole, with 328 prescriptions and refills. In total Rajeev Kulkarni wrote 2,215 Medicare prescriptions that cost $9.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 328 | 772 | 77 | $4,759 |
| Imbruvica Ibrutinib | 154 | 154 | 15 | $2.4M |
| Eliquis Apixaban | 130 | 161 | 30 | $88K |
| Gabapentin Generic | 108 | 120 | 22 | $777 |
| Lenalidomide Generic | 87 | 87 | Under 11 | $1.2M |
| Prednisone Generic | 75 | 83 | 29 | $237 |
| Acyclovir Generic | 73 | 119 | 14 | $798 |
| Hydroxyurea Generic | 71 | 190 | 21 | $1,590 |
| Ondansetron Odt Ondansetron | 70 | 70 | 41 | $1,269 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 60 | 60 | 24 | $2,197 |
| Tamoxifen Citrate Generic | 57 | 131 | 13 | $1,583 |
| Levothyroxine Sodium Generic | 40 | 51 | Under 11 | $139 |
| Ibrance Palbociclib | 39 | 39 | Under 11 | $612K |
| Calquence Acalabrutinib Maleate | 36 | 36 | Under 11 | $529K |
| Exemestane Generic | 36 | 48 | Under 11 | $2,887 |
Brand drugs: 666 claims; generic drugs: 1,549 claims; opioid claims: 173.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rajeev Kulkarni $2,345 ($2,345 in general payments such as food, travel and fees) from 40 companies. The largest payer was Novartis Pharmaceuticals Corporation with $319.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 17 | $319 |
| Pfizer Inc. PFE | 10 | $191 |
| Daiichi Sankyo Inc. 4568.T | 8 | $164 |
| Celgene Corporation BMY | 11 | $164 |
| Gilead Sciences, Inc. GILD | 8 | $161 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 5 | $159 |
| Abbvie Inc. ABBV | 6 | $156 |
| SpringWorks Therapeutics, Inc. | 2 | $75.91 |
| GlaxoSmithKline, LLC. GSK | 4 | $67.08 |
| Astellas Pharma US Inc 4503.T | 3 | $62.87 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.